The most active ASX ticker today is IHL.AX stock, trading at A$0.041 as of this intraday update on 05 Mar 2026. Volume has surged to 61,360,016 shares, nearly ten times the average, driving a -10.87% move from yesterday’s close of A$0.046. Traders are reacting to thin market depth, a long-term low of A$0.041, and continued clinical-program newsflow in the healthcare sector. This piece examines trading activity, fundamentals, technicals, and price forecasts for Incannex Healthcare Limited on the ASX.

IHL.AX stock intraday trading activity

Intraday, Incannex Healthcare Limited (IHL.AX) opened at A$0.047 and hit a high of A$0.051 and a low of A$0.041. The stock shows 61,360,016 shares traded versus an average volume of 6,427,691, a relative volume of 9.55, indicating outsized retail or block trading. High volume with a falling price implies selling pressure and low liquidity on the ASX.

Catalysts and IHL.AX stock news flow

Incannex remains news-driven because its pipeline includes IHL-42X and psychedelic programs now in clinical stages, which influence sentiment. Recent international coverage has appeared on Investing.com summarising the company’s trial programs and ADR listings source. Market reaction today likely reflects thin liquidity and headlines rather than fresh regulatory decisions source.

Fundamentals and valuation snapshot for IHL.AX stock

Incannex reports a market cap of A$14,255,927 and 347,705,540 shares outstanding, with trailing EPS of -1.30 and a negative P/E of -0.03. Cash per share is 0.0217, book value per share is 0.0547, and price-to-book is 0.75, indicating the market values the company below book. Current ratio is 9.02, reflecting a strong short-term liquidity position but persistent operating losses due to high R&D spend.

Technical picture and trading levels for IHL.AX stock

Price sits at A$0.041, below the 50-day average A$0.065 and the 200-day average A$0.103, showing a clear downtrend on longer-term moving averages. Key support is the year low A$0.041 and resistance sits near A$0.065 and A$0.103. High volume on a down day raises short-term volatility and increases probability of range expansion or capitulation.

Meyka AI rates IHL.AX with a score out of 100

Meyka AI rates IHL.AX with a score out of 100: 65.07 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects robust cash ratios and book value, offset by negative earnings, weak revenue per share, and high pipeline execution risk. These grades are not guaranteed and are for informational purposes only.

Price targets, scenarios and IHL.AX stock forecast

Analyst coverage is limited; we outline scenario ranges to frame risk. Realistic base-case target: A$0.06, upside target: A$0.14, downside support: A$0.02. Meyka AI’s forecast model projects A$0.095 within 12 months compared with the current A$0.041, implying an upside of 131.71%. Forecasts are model-based projections and not guarantees.

Final Thoughts

Intraday activity makes IHL.AX stock one of the ASX’s most active small caps on 05 Mar 2026, with price at A$0.041 and volume of 61,360,016 signalling elevated volatility. Short-term traders should treat the move as liquidity-driven given the relative volume of 9.55, the stock’s position below the 50-day A$0.065 and 200-day A$0.103 averages, and thin order books. From a fundamentals angle, Incannex holds A$0.0217 cash per share and a price-to-book of 0.75, but EPS remains -1.30 and revenue per share is minimal, reflecting an R&D-heavy biotech profile. Meyka AI’s model projects A$0.095 within 12 months, an implied upside of 131.71% versus A$0.041 today; that projection reflects trial milestones and a successful commercial pathway as upside drivers. For risk management, consider position sizing given potential swings between the downside support A$0.02 and the bullish target A$0.14. Visit the IHL.AX page on Meyka for real-time tools and our AI-powered market analysis. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.